HighField Biopharmaceuticals’ mRNA-based HFG1 Demonstrates Potential as a Longer Acting GLP-1R Agonist for Diabetic Control and Weight Loss
June 24 2024 - 5:30AM
Business Wire
Preclinical results in naturally occurred
diabetic monkeys were presented at the American Diabetes
Association 84th Scientific Sessions, June 21-24, 2024
HighField plans on filing a U.S. IND for HFG1
in Q3/2024
HighField Biopharmaceuticals, a clinical stage company using
lipid-based therapeutics to treat cancer, diabetes and other
diseases, said today naturally occurred diabetic monkeys
experienced weight loss and HbA1c level reduction during an
assessment period of two months following a single injection with
HFG1. The data were presented at the American Diabetes Association
(ADA) 84th Scientific Sessions June 21-24, 2024, in Orlando,
FL.
HFG1 is an mRNA-based GLP-1R agonist encoding a fusion protein
of a GLP-1 analogue and a pH sensitive binder of human FcRn. The
mRNA is loaded in proprietary lipid nanostructure particles (LNPs)
designed for subcutaneous administration and local mRNA delivery.
The proteins expressed are secreted and distributed into systemic
circulation.
The abstract, titled “Preliminary study of efficacy and duration
of an mRNA based GLP-1R agonist in diabetic monkeys,” is published
on the website of the ADA’s journal Diabetes. HighField CEO and
Scientific Founder Yuhong Xu, Ph.D., made the presentation of the
full poster.
“We are very encouraged by the results and we are planning to
file a US IND by third quarter of this year,” said Dr. Xu. “Our
LNPs were developed with membrane stabilized structures. Unlike
traditional LNPs for mRNA vaccination, they are more stable for
storage and after injection. There was more sustained production of
the transgene, enabling the GLP-1R agonist activity to be longer
lasting for weeks and months. Consequently far fewer injections
would be needed than existing GLP-1 products.”
The monkeys were closely monitored following HFG1 injections.
The monkeys showed no serious adverse effects. They did, however,
experience a reduced appetite for the first week following
injection, after which their appetite returned to normal. Weight
loss and A1C (HbA1c) reduction were significant.
About HighField Biopharmaceuticals
HighField is a clinical stage company focused on novel
applications of liposome constructs directed to immuno-oncology and
other disease treatments. The company also has a research and
development center and a GMP-compliant production facility.
HighField’s lead clinical development program is HFK16, a drug
encapsulated immune modulating liposome. The company’s pipeline
also includes an ADC platform comprised of drug encapsulated
immunoliposomes for solid tumors as well as LNP therapeutics for
gene delivery and gene therapy. For more information visit
https://highfield.bio.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240624046397/en/
Media Contact: Dan Eramian Opus Biotech Communications
danieleramian@comcast.net 425-306-8716
Business Development Contact: Donald Wyatt HighField
Biopharmaceuticals dwyatt@hf-biopharm.com 206-356-8196